ASAkihisa Sawada

Akihisa Sawada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akihisa Sawada has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Maho Sato

    23Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan

    4 shared publications
  • Masami Inoue

    Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Izumi city, Japan

    4 shared publications
  • Kohei Higuchi

    Department of Hematology and Oncology, Osaka Women’s and Children’s Hospital, Osaka 594-1101, Japan

    3 shared publications
  • Ayako Arai

    Department of Hematology and Biophysical Systems Analysis, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan

    2 shared publications
  • Chizuko Sakashita

    Department of Hematology Tokyo Medical and Dental University (TMDU) Tokyo Japan

    2 shared publications
  • Keisei Kawa

    Osaka Women's and Children's Hospital

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell–type chronic active EBV infection

    by Ryo Akazawa, Takashi Mikami, Masaki Yamada, Itaru Kato, Hirohito Kubota, Satoshi Saida, Yoshinori Uchihara, Yuriko Ishikawa, Tatsuya Kamitori, Keiji Tasaka, et al.

    Chronic active Epstein-Barr virus (EBV) infection (CAEBV) is an orphan disease characterized by the proliferation and infiltration of EBV-infected T/natural killer (NK) cells into multiple organs. Although CAEBV is a heterogeneous disease with diverse clinical courses, its pathogenesis remains poorly understood. In this study, we explored the molecular mechanisms underlying CAEBV by performing a comprehensive multiomics analysis, including genome, transcriptome, epigenome, and single-cell transcriptome and surface proteome analyses, of 65 patients with CAEBV. Methylation analysis identified 2 distinct subtypes of NK cell–type CAEBV based on the CpG island methylator phenotype (CIMP). In CIMP-positive CAEBV, regions associated with enhancer of zeste homolog 2 binding sites and histone H3 lysine 27 trimethylation exhibited increased DNA hypermethylation, resulting in downregulation of tumor suppressor and antiherpesvirus genes. CIMP-positive CAEBV had a particularly poor prognosis and displayed a “neoplastic” phenotype with a DNA methylation pattern similar to that of extranodal NK/T-cell lymphoma, a higher tumor mutation burden, and frequent copy number alterations. In addition, both in vitro and in vivo functional assays demonstrated that 5-azacytidine, a hypomethylating agent, was a potentially effective agent for high-risk CIMP-positive CAEBV. Finally, we established a method to effectively detect EBV-infected cells in single-cell analysis, suggesting that EBV-infected NK cells have tissue-resident properties and that innate and adaptive immunity to EBV is compromised in patients with CAEBV. The present findings provide insight into the complex molecular features of CAEBV and suggest potential molecular therapies.


  • Open Access

    Changes in body mass index during chemotherapy are positively associated with height outcome in childhood cancer survivors of acute lymphoblastic leukemia

    by Tamaki Wada, Ayaha Hata, Takatoshi Maeyama, Shinobu Ida, Kohei Higuchi, Maho Sato, Akihisa Sawada, Yuri Etani, Masanobu Kawai

    Impaired linear growth is an important morbidity in childhood cancer survivors (CCS); however, chemotherapy-associated factors that affect height outcomes remain elusive. Accordingly, we conducted a single-center, retrospective cohort study that included survivors of childhood-onset acute lymphoblastic leukemia (ALL) diagnosed between 2002 and 2021 who achieved complete remission through chemotherapy alone. Anthropometric parameters and treatment protocols were evaluated based on medical records. Individuals with background disorders or impaired growth were excluded from the study. Associations between anthropometric parameters during chemotherapy and height standard deviation scores (height-SDS) at the current visit were investigated. The results are expressed as the median (interquartile range). Seventy-three individuals (males, N = 44) were included in the study. The median age (years) at diagnosis, end of chemotherapy, and current visit were 4.2 (3.2 to 7.9), 6.3 (5.1 to 10.0), and 15.9 (11.4 to 19.2), respectively. Height-SDS at diagnosis was –0.25 (–0.65 to 0.35), which significantly declined during chemotherapy and recovered thereafter, resulting in a current height-SDS of –0.31 (–0.84 to 0.22). The height-SDS at the investigated time points and its changes during chemotherapy did not differ among the treatment protocols. Multivariate analysis revealed that height-SDS at the current visit was positively associated with changes in body mass index (BMI)-SDS during chemotherapy (β = 0.22, p = 0.01) after adjusting for sex, current age, height-SDS at diagnosis, changes in height-SDS during chemotherapy, and treatment protocols. Since changes in BMI are potentially influenced by nutritional status, our results may underscore the importance of nutritional status during chemotherapy on height outcomes in childhood ALL survivors.


  • Open Access

    Multiplex Real-Time PCR-Based Newborn Screening for Severe Primary Immunodeficiency and Spinal Muscular Atrophy in Osaka, Japan: Our Results after 3 Years

    by Tomokazu Kimizu, Masatoshi Nozaki, Yousuke Okada, Akihisa Sawada, Misaki Morisaki, Hiroshi Fujita, Akemi Irie, Keiko Matsuda, Yuiko Hasegawa, Eriko Nishi, et al.

    In newborn screening (NBS), it is important to consider the availability of multiplex assays or other tests that can be integrated into existing systems when attempting to implement NBS for new target diseases. Recent developments in innovative testing technology have made it possible to simultaneously screen for severe primary immunodeficiency (PID) and spinal muscular atrophy (SMA) using quantitative real-time polymerase chain reaction (qPCR) assays. We describe our experience of optional NBS for severe PID and SMA in Osaka, Japan. A multiplex TaqMan qPCR assay was used for the optional NBS program. The assay was able to quantify the levels of T-cell receptor excision circles and kappa-deleting recombination excision circles, which is useful for severe combined immunodeficiency and B-cell deficiency screening, and can simultaneously detect the homozygous deletion of SMN1 exon 7, which is useful for NBS for SMA. In total, 105,419 newborns were eligible for the optional NBS program between 1 August 2020 and 31 August 2023. A case each of X-linked agammaglobulinemia and SMA were diagnosed through the optional NBS and treated at early stages (before symptoms appeared). Our results show how multiplex PCR-based NBS can benefit large-scale NBS implementation projects for new target diseases.


  • Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan

    by Masahide Yamamoto, Maho Sato, Yasushi Onishi, Yoji Sasahara, Hideki Sano, Masayoshi Masuko, Hirohisa Nakamae, Ken‐Ichi Matsuoka, Takahide Ara, Kana Washio, et al.

    The effects of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) on systemic chronic active Epstein–Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo‐HSCT. The median age at HSCT was 21 years, and the three‐year overall survival (3‐year OS) rate was 72.5%. Of the 90 patients whose viral load after allo‐HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV‐DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15–39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98–59.56, p = .006) and 15.93 (95% CI: 2.45–103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL‐2 receptor (sIL‐2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL‐2R level (≥2000 U/mL) showed a poorer prognosis. Although allo‐HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high‐risk patients, especially those with high levels of sIL‐2R.


  • Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children

    by Akihisa Sawada, Mariko Shimizu, Maho Koyama-Sato, Kohei Higuchi, Yosuke Okada, Kimitoshi Goto, Shota Inoue, Masahiro Yasui, Masami Inoue

    Graft failure is a major pitfall of unrelated umbilical cord blood transplantation (CBT) in children with rare hematological disorders other than acute leukemia, such as acquired and inherited bone marrow failure, myelodysplastic syndrome, juvenile myelomonocytic leukemia, and chronic myeloid leukemia. We developed a less-toxic conditioning regimen for CBT that achieves a higher rate of complete donor chimerism, and retrospectively compared it against two other conditioning regimens for CBT performed at our single institution. The engraftment rate with complete donor chimerism was 100% and 5-year event-free survival (5y-EFS) was 90.9% in patients using our latest regimen (n = 11) of reduced-intensity conditioning (RIC) containing fludarabine (Flu) 180 mg/m2, melphalan (MEL) 210 mg/m2, and low-dose rabbit anti-thymocyte globulin (LD-rATG) 2.5 mg/kg without irradiation (regimen C). Outcomes were better than in patients (n = 10) treated with previous regimens involving irradiation (5y-EFS 30.0%, p = 0.004): regimen A, consisting of myeloablative conditioning containing cyclophosphamide (CY) and total body irradiation (TBI) with 8–12 Gy, or regimen B, consisting of RIC with Flu, CY, horse ATG, and thoracoabdominal irradiation (TAI) with 6 Gy. In conclusion, Flu/MEL/LD-rATG (regimen C) without TBI/TAI may be preferable as RIC for unrelated CBT in children with rare hematological disorders.


  • Two cases of pregnancy after achieving complete remission of chronic active Epstein–Barr virus infection

    by Nanayo Sasagasako, Aiko Kakigano, Chizuko A. Kamiya, Akihiro Tsuji, Akihisa Sawada, Jun Yoshimatsu

    Chronic active Epstein–Barr virus (CAEBV) infection characterized by persistent infectious mononucleosis-like symptoms can lead to cardiovascular diseases. We encountered two pregnant women with CAEBV histories complicated with cardiovascular diseases. A 36-year-old woman with a history of myocardial infarction due to CAEBV and coronary artery bypass grafting became pregnant. Her left ventricular ejection fraction (LVEF) decreased, and cesarean section was performed at 36 weeks of gestation. Her LVEF recovered after delivery. A 32-year-old woman with a history of CAEBV and chronic hypertension was diagnosed with mild pulmonary arterial hypertension (PAH) after conception. She strongly desired to continue the pregnancy. She became complicated with severe superimposed preeclampsia at 31 weeks of gestation, and cesarean section was performed. Her PAH did not deteriorate during pregnancy or the postpartum period. Women treated for CAEBV, even with complete remission, require a preconception evaluation focused on the cardiovascular system and careful management of their pregnancy.


  • Open Access

    Measurable residual disease-based strategy and reduced-intensity hematopoietic stem cell transplantation for acute myelogenous leukemia in children

    by Akihisa Sawada, Sadao Tokimasa, Masahiro Yasui, Maho Sato, Kohei Higuchi, Mariko Shimizu, Osamu Kondo, Keisei Kawa, Masami Inoue

    Background. Measurable residual disease (MRD) is a powerful prognostic factor in patients with acute myelogenous leukemia (AML). We previously conducted a prospective study on an MRD-based strategy for the treatment of children with AML, and its significance has been reported. The present retrospective study is a pooled analysis of 34 patients who were registered after the completion of the previous study. Procedure. Reduced-intensity conditioning (RIC) followed by allogeneic hematopoietic stem cell transplantation (RIC-HSCT) was adopted to increase survival rates and minimize toxicities. The strategy was also refined with a minor modification, with WT1 expression levels in peripheral blood, as an MRD marker after a 2nd course of chemotherapy (consolidation course 1), being measured in addition to WT1, chimeric mRNA, and aberrant surface markers in bone marrow. Results. Five-year relapse-free and overall survival rates were 76.5 and 85.2%, respectively. RIC-HSCT was safely and effectively performed on MRD-positive patients. Among patients who underwent RIC-HSCT, re-emerging/rising MRD and high levels of MRD before HSCT were risk factors for disease relapse early after HSCT. Conclusions. The MRD-based strategy and RIC-HSCT worked well for children with AML. HLA-haploidentical peripheral blood transplantation following RIC may be a promising candidate for further study on patients at very high risk of relapse.

  • Open Access

    Treatment Outcomes of Langerhans Cell Histiocytosis: A Retrospective Study

    by Kazuhiko Hashimoto, Shunji Nishimura, Naoki Sakata, Masami Inoue, Akihisa Sawada, Masao Akagi

    Background and Objectives: Langerhans cell histiocytosis (LCH) is a rare disease characterized by the infiltration of one or more organs by Langerhans cell-like dendritic cells. LCH often involves the bone, and its clinical evidence is limited. The purpose of this study is to report on the treatment of LCH at our institution and to add to the evidence for LCH. Materials and Methods: We reviewed six cases of LCH treated in our hospital between November 2005 and February 2016. Patient age at the first visit, sex, site of origin, symptoms, image tools used for diagnosis, biopsy site, complications, treatment, and final clinical outcome were evaluated. The median follow-up period was 41 months. Results: The median patient age at the first visit was 13.5 years. Three male and three female individuals were enrolled. Multiple lesions were observed in five cases, and a solitary lesion was observed in one case. Pain was the chief complaint in five cases. Radiography was the most commonly used imaging tool. Bone scintigraphy or magnetic resonance imaging and positron emission tomography-computed tomography were also used to diagnose systematic LCH. Biopsy of the femur was performed in two cases, and biopsy of the tibia, lumbar vertebrae, rib, and radius was performed in one case each. Regarding comorbidities, one case of hepatitis B and one case of autism were observed. Chemotherapy was initiated in two patients. The other four patients were observed naturally. Continuous disease-free survival was observed in five patients. One patient remained alive but not without disease during the final follow-up examination. Conclusion: LCH should be diagnosed as early as possible to treat it appropriately.


  • Open Access

    Narrative review of chronic active EBV infection—advances in clinical management

    by Akihisa Sawada, Masami Inoue

    Chronic active Epstein-Barr virus infection (CAEBV) is a prototype of EBV-associated T- and NK-cell lymphoproliferative diseases (T/NK-cell LPDs). It is a highly progressive disease with fatal organ failure, severe hypercytokinemia [“CAEBV flare”; including hemophagocytic lymphohistiocytosis (HLH)], and overt lymphomatous/leukemic changes. Children and adolescents with CAEBV mostly die within 5–10 years. The progression of adult-onset CAEBV is two-fold faster. We herein present a narrative review. Since CAEBV is a rare disease, limited information is currently available on its treatment. Therefore, we describe our experience of treating CAEBV in addition to a literature review. CAEBV shows a spectrum for its severity and neoplastic nature. Patients will not recover without radical treatment, and mostly require allogeneic hematopoietic stem cell transplantation (HSCT). We established a treatment strategy comprising three steps: cooling [immunochemotherapy with prednisolone (PSL), cyclosporine A (CsA), and etoposide (Etp)], cytoreduction (multidrug-combination block chemotherapy), and reconstruction (allogeneic HSCT). The three-step strategy is applicable to patients at any status of the CAEBV spectrum for improved survival and quality of life. The 3-year overall survival (OS) rate was 76%. Planned HSCT with stable disease or a less active disease status has been successfully performed, and the OS rate is approximately 90%. In contrast, the prognosis of patients with severe disease activity even after chemotherapy is poor (OS rate <20%). Since CAEBV is a progressive disease, the earlier initiation of therapy to complete whole treatment in advance results in better survival. We also discuss new drugs and immunotherapies for CAEBV.


  • Dynamics of Epstein-Barr virus after cord blood transplantation: A nationwide survey in Japan

    by Akihisa Sawada, Shuichi Taniguchi, Satoshi Takahashi, Masami Inoue, Yasushi Onishi, Masatsugu Tanaka, Hideho Henzan, Masayuki Kubo, Aya Nishida, Keisei Kawa

    Epstein-Barr virus (EBV) is a common virus that latently infects most adults and has a tropism to B lymphocytes. In 1988, two cases of EBV infection were reported to be eradicated by hematopoietic stem cell transplantation from an EBV-negative donor. However, the dynamics of EBV after cord blood transplantation (CBT), namely, the kinetics of anti-EBV antibodies, the incidence of negative/adverse seroconversion (from positive to negative), and the clinical course of re-infection (second primary infection) by EBV, have not yet been characterized in detail. Therefore, we performed a nationwide survey that focused on the dynamics of EBV after CBT 1 year or later after CBT. Negative seroconversion occurred in 23% of previously EBV-infected patients. The incidence of late-onset EBV-associated events was 1.9% (13/674): 5 infectious mononucleosis, 2 hemophagocytic lymphohistiocytosis (HLH), and 6 remaining typical lymphoproliferative disease. HLH occurred in newly infected patients (primary or second primary) and also in those with reactivation and was fatal. The annual monitoring of anti-EBV antibody titers may facilitate the early detection of these late-onset EBV-associated events and treatment initiation before disease progression.